Find information on thousands of medical conditions and prescription drugs.

Lantus

Lantus is a long-acting basal insulin analogue, usually given once or twice daily to help control the blood sugar level of those with diabetes. Its theoretical advantage is that it has a 24 hour duration of action, with a "peakless" profile. Thus, it more closely resembles the basal insulin secretion of the normal pancreatic beta cells. In type 2 diabetes and in combination with a short acting sulphonylurea (drugs which stimulate the pancreas to make more insulin), it can offer moderate control of serum glucose levels. more...

Home
Diseases
Medicines
A
B
C
D
E
F
G
H
I
J
K
L
Labetalol
Lacrisert
Lactitol
Lactuca virosa
Lactulose
Lamictal
Lamisil
Lamivudine
Lamotrigine
Lanophyllin
Lansoprazole
Lantus
Lariam
Larotid
Lasix
Latanoprost
Lescol
Letrozole
Leucine
Leucovorin
Leukeran
Levaquin
Levetiracetam
Levitra
Levocabastine
Levocetirizine
Levodopa
Levofloxacin
Levomenol
Levomepromazine
Levonorgestrel
Levonorgestrel
Levophed
Levora
Levothyroxine sodium
Levoxyl
Levulan
Lexapro
Lexiva
Librium
Lidocaine
Lidopen
Linezolid
Liothyronine
Liothyronine Sodium
Lipidil
Lipitor
Lisinopril
Lithane
Lithobid
Lithonate
Lithostat
Lithotabs
Livostin
Lodine
Loestrin
Lomotil
Loperamide
Lopressor
Loracarbef
Loratadine
Loratadine
Lorazepam
Lortab
Losartan
Lotensin
Lotrel
Lotronex
Lotusate
Lovastatin
Lovenox
Loxapine
LSD
Ludiomil
Lufenuron
Lupron
Lutropin alfa
Luvox
Luxiq
Theophylline
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

In the absence of endogenous insulin (Type 1 diabetes or depleted type 2), Lantus needs the support of a fast acting insulin taken with food to reduce the effect of prandially derived glucose. It is post-prandial glucose elevation which more significantly affects HbA1c and thus determines the progression of the long-term complications of diabetes mellitus.

The peakless profile of Lantus also enables the dose to be relatively higher than standard NPH insulin. Because standard NPH is normally administered at night, its peak of action tends to coincide with the lower serum glucose levels associated with nocturnal metabolism. This can induce nocturnal hypoglycaemia. Lantus offers the benefit of a more consistent pharmacological dynamic without nocturnal hypoglycaemia. The result of this is a patient who feels more confident and more comfortable with a lower pre-bed and pre-breakfast capillary glucose level.


Lantus is formulated at pH4, whereby it is completely soluble. Upon injection, it is neutralized leading to the release small precipitates. This ensures that small amount of Lantus is released into the body continuously, giving a peakless profile

Read more at Wikipedia.org


[List your site here Free!]


FDA approves Lantus—once-daily, long-acting insulin - Brief Article
From Drug Store News, 5/22/00 by Kim Roller

The FDA has approved Lantus (insulin glargine [rDNA origin] injection) for the treatment of type 2 and type 1 diabetes, the first long-acting recombinant human insulin analog with once-daily administration and 24-hour glucose-lowering effect to be approved by the FDA. Aventis Pharmaceuticals, the U.S. pharmaceutical arm of Aventis Pharma AG, plans to have the product available for patients later this year.

Lantus is indicated for once-daily subcutaneous administration at bedtime in the treatment of adult patients with type 2 diabetes who require basal (long-acting) insulin for the control of hyperglycemia and for adult and pediatric patients with type 1 diabetes.

A recombinant human insulin analogue, in clinical trials Lantus demonstrated similar levels of efficacy, in regard to metabolic control, as NPH human insulin. In clinical studies, Lantus showed a slower, more prolonged absorption, Aventis said, and a relatively constant concentration/time profile over 24 hours with no pronounced peak in comparison to NPH human insulin.

COPYRIGHT 2000 Lebhar-Friedman, Inc.
COPYRIGHT 2000 Gale Group

Return to Lantus
Home Contact Resources Exchange Links ebay